echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood Cancer J: High-dose methotrexate can effectively prevent isolated CNS recurrence in DLBCL patients

    Blood Cancer J: High-dose methotrexate can effectively prevent isolated CNS recurrence in DLBCL patients

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    1-14% of patients with diffuse large B-cell lymphoma (DLBCL) will have a central nervous system (CNS) recurrence.
    Such patients have a poor prognosis, with a survival period of only 2-5 months
    .


    In view of concerns thatthe effectiveness ofintrathecal (IT) prevention may not reach a detectable concentration in the brain parenchyma, some guidelines recommend that patients with a high risk of CNS recurrence should be treated with systemic high-dose methotrexate (HDMTX) prophylaxis


    1-14% of patients with diffuse large B-cell lymphoma (DLBCL) will have a central nervous system (CNS) recurrence.


    This is a retrospective study in which researchers evaluated the effects of preventive HDMTX on isolated CNS recurrence, CNS and systemic co-recurrence, systemic recurrence, and survival prognosis
    .


    A total of 226 newly diagnosed DLBCL patients were enrolled, all of whom received RCHOP treatment and had a high-risk CNS International Prognostic Index (CNS-IPI) score


    Cumulative recurrence rate of solitary CNS

    Cumulative recurrence rate of solitary CNS

    Compared with patients who did not receive prophylactic HDMTX, patients who received prophylactic HDMTX had a significantly lower 3-year risk of isolated CNS recurrence (3.
    1% vs 14.
    6%, p=0.
    032)
    .


    However, in the multivariate analysis, there were no significant differences in CNS-systemic recurrence, systemic recurrence, 3-year progression-free survival (PFS) and overall survival (OS) between the two groups


    Compared with patients who did not receive prophylactic HDMTX, patients who received prophylactic HDMTX had a significantly lower 3-year solitary CNS recurrence risk.


    PFS and OS of the total test population

    PFS and OS of the total test population

    Among patients with matching propensity scores (n=102), HDMTX was also significantly associated with a lower rate of solitary CNS recurrence (HR 0.
    06, 95% CI 0.
    004–0.
    946, p=0.
    046)
    .


    On the third day of RCHOP chemotherapy, HDMTX was well tolerated and the toxicity was controllable when the dose was 3 g/m2


    In patients with propensity score matching (n=102), HDMTX was also significantly associated with a lower rate of solitary CNS recurrence.


    Preventive HDMTX can reduce the recurrence rate of isolated CNS.


    Original source:

    Ong, SY, de Mel, S.


    High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.